Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (303)	9/6/1999 5:45:00 PM
From: Gordon James	Respond to of 666

DAK, From what I've seen regarding the nature of the remaining FDA issues, I have to agree with your call that we're getting a great buying opportunity here. I wouldn't be surprised to see a re-test of the recent low of 18 5/8, so I'm out doing some more fishing with a couple of limit buy orders between here and there... Busting below 18 and the support we've seen in that range would be a problem, IMO, but I don't think its a terrible bet that support in that range will hold (I'm not any kind of TA expert, but that doesn't seem to stop me from jabbering like one, does it? ;-) Gordon

To: LLCF who wrote (303)	9/7/1999 11:10:00 PM
From: synchro	Respond to of 666

I think it is human nature for people to look at the past track record of a company. A submission by Pfizer or Merck probably will get more benefit of the doubt than a new biotech outfit with no previously proven clinical trial success. Now, SmithKline supposedly is in the league of Pfizer and Merck when it comes to experience in dealing with FDA and designing clinical trials. Perhaps the fact that they're a foreign company has something to do with their failure to properly advise Coulter on just exactly what FDA wanted. I do think there's an element of hubris on behalf of Coulter's management team that's somewhat disturbing. I come back to my previous comment, "Do as you're told, not what you think should be done." From my own experience of dealing with state insurance departments as an actuary, I would say the process of bureacratic reivew is highly subjective and individual, yet unbelievably inflexible and dense. A wrongly chosen word in your documentation, a failure to number the forms correctly, sloppiness in the packaging of filing material--all these things can trigger the dreaded "objection" letter. In the end, what can you do? Appeal to reason? forget about it. This is not about reason, compassion or rationality; this is about some bureaucrats hell bent on covering their own ass. And by God you better help them cover their ass by making a meticulous filing on the first try. To me Coulter is a risky investment at this stage. I think there's still plenty of money to be made after the filing ends up going thru. You may miss the initial pop, but you also avoid another gut-wrenching plunge.